RV-PA uncoupling is associated with increased mortality in transthyretin amyloid cardiomyopathy treated with tafamidis

被引:0
|
作者
Schwarting, Stephanie K. [1 ,2 ]
Poledniczek, Michael [2 ,3 ]
Metodiev, Yuliyan [1 ]
Stolz, Lukas [1 ]
Hofmann, Eva [2 ]
Hegenbart, Ute [4 ]
Schoenland, Stefan [4 ]
Kaeaeb, Stefan [1 ,5 ]
Massberg, Steffen [1 ]
Frey, Norbert [2 ]
Aus Dem Siepen, Fabian [2 ]
机构
[1] LMU Univ Hosp Munich, Dept Med 1, Marchionini str 15, D-81377 Munich, Germany
[2] Univ Hosp Heidelberg, Dept Cardiol Angiol & Resp Med, Neuenheimer Feld 410, Heidelberg, Germany
[3] Med Univ Vienna, Dept Internal Med 2, Div Cardiol, Vienna, Austria
[4] Univ Hosp Heidelberg, Dept Internal Medicine5, Neuenheimer Feld 410, Heidelberg, Germany
[5] European Reference Network Rare Low Prevalence & C, Amsterdam, Netherlands
关键词
RV-PA coupling; Amyloidosis; Transthyretin; Echocardiography; TAPSE/PASP-ratio; HEART-FAILURE; CLINICAL-OUTCOMES; PROGNOSTIC VALUE; REPAIR; IMPACT;
D O I
10.1007/s00392-024-02576-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The right ventricle to pulmonary artery coupling (RV-PAc) describes the right ventricle's ability to adjust to an increased afterload. In case of transthyretin amyloid cardiomyopathy (ATTR-CM), impaired RV-PAc can result from increased left ventricular diastolic stiffness due to fibril deposition. Objectives While RV-PAc is a validated prognostic parameter in pulmonary arterial hypertension (PAH), its prognostic relevance in ATTR-CM remains unknown. We sought to evaluate the prognostic implications of impaired RV-PAc on survival in ATTR-CM. Methods In this multicentre study, RV-PAc was investigated by the echocardiographic surrogate of ratio of tricuspid annular plane systolic excursion to estimated pulmonary arterial systolic pressure (TAPSE/PASP) in 418 ATTR-CM patients, all treated with a TTR stabilizer. The primary outcome was all-cause mortality. Results Within a median time of 1.52 [IQR 0.72-2.56] years after diagnosis, 49 (11.7%) patients died. In multivariate Cox regression analysis impaired RV-PAc was a strong independent predictor of mortality (Hazard Ratio (HR) 2.16, 95% Confidence Interval (CI) 1.14-4.07, p = 0.018). RV-PAc ratio at first presentation emerged as a robust marker for risk stratification with a determined optimal cut-off of 0.382 mm/mmHg (area under the curve (AUC) 0.73, 95% CI 0.65-0.81). Patients with RV-PAc ratio <= 0.382 mm/mmHg exhibited significantly lower survival (HR 4.17, 95% CI 2.21-7.87, p < 0.001) within 3 years of follow up than those with RV-PAc ratio above the cut-off (Graphical Abstract). Conclusion Impaired adaptation of the RV to increased afterload is associated with worse outcome in ATTR-CM patients. RV-PAc ratio can serve as an echocardiographic predictor for all-cause mortality. Therefore, the determination of RV-PAc could improve risk stratification for ATTR-CM patients.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Effects of tafamidis on quantification of myocardial amyloid deposits in patients with transthyretin amyloid cardiomyopathy
    Rettl, R.
    Wollenweber, T.
    Mann, C.
    Duca, F.
    Dachs, T.
    Binder, C.
    Stojanovic, M.
    Ligios, L. Camuz
    Schrutka, L.
    Dalos, D.
    Charwat-Resl, S.
    Hengstenberg, C.
    Eslam, R. Badr
    Kastner, J.
    Hacker, M.
    Bonderman, D.
    WIENER KLINISCHE WOCHENSCHRIFT, 2021, 133 (SUPPL 3) : S105 - S106
  • [42] Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)
    Hanna, Mazen
    Damy, Thibaud
    Grogan, Martha
    Stewart, Michelle
    Gundapaneni, Balarama
    Patterson, Terrell A.
    Schwartz, Jeffrey H.
    Sultan, Marla B.
    Maurer, Mathew S.
    AMERICAN JOURNAL OF CARDIOLOGY, 2021, 141 : 98 - 105
  • [43] Effects of tafamidis on quantification of myocardial amyloid deposits in patients with transthyretin amyloid cardiomyopathy
    Rettl, R. Rene
    Wollenweber, T.
    Mann, C.
    Duca, F.
    Dachs, T-M
    Binder, C.
    Stojanovic, M.
    Ligios, L. Camuz
    Schrutka, L.
    Dalos, D.
    Charwat-Resl, S.
    Eslam, R. Badr
    Kastner, J.
    Hacker, M.
    Bonderman, D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 253 - 253
  • [44] Specific Therapy in Transthyretin Amyloid Cardiomyopathy Future Perspectives Beyond Tafamidis
    Saro, Riccardo
    Allegro, Valentina
    Merlo, Marco
    Dore, Franca
    Sinagra, Gianfranco
    Porcari, Aldostefano
    HEART FAILURE CLINICS, 2024, 20 (03) : 343 - 352
  • [45] Effect of tafamidis on left atrial function in patients with transthyretin amyloid cardiomyopathy
    Uemura, K.
    Ichikawa, Y.
    Nagai, S.
    Takeuchi, M.
    Nishihara, Y.
    Takeuchi, K.
    Oota, E.
    Odajima, S.
    Kintsu, M.
    Todo, S.
    Fukuda, T.
    Hisamatsu, E.
    Hirata, K.
    Tanaka, H.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [46] Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
    Elliott, Perry
    Drachman, Brian M.
    Gottlieb, Stephen S.
    Hoffman, James E.
    Hummel, Scott L.
    Lenihan, Daniel J.
    Ebede, Ben
    Gundapaneni, Balarama
    Li, Benjamin
    Sultan, Marla B.
    Shah, Sanjiv J.
    CIRCULATION-HEART FAILURE, 2022, 15 (01) : E008193
  • [47] Five-year Survival With Tafamidis In Patients With Transthyretin Amyloid Cardiomyopathy
    Hoffman, James E.
    Gundapaneni, Balarama
    Sultan, Marla B.
    Elliott, Perry
    JOURNAL OF CARDIAC FAILURE, 2022, 28 (05) : S102 - S102
  • [48] Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy
    Rettl, Rene
    Wollenweber, Tim
    Duca, Franz
    Binder, Christina
    Cherouny, Bernhard
    Dachs, Theresa-Marie
    Ligios, Luciana Camuz
    Schrutka, Lore
    Dalos, Daniel
    Beitzke, Dietrich
    Loewe, Christian
    Eslam, Roza Badr
    Kastner, Johannes
    Hacker, Marcus
    Bonderman, Diana
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2023, 24 (08) : 1019 - 1030
  • [49] Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy
    Damy, T.
    Elliott, P.
    Gundapaneni, B.
    Tai, S. See
    Sultan, M. B.
    Drachman, B. M.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2142 - 2142
  • [50] Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis
    Camille Vong
    Martin Boucher
    Steve Riley
    Lutz O. Harnisch
    American Journal of Cardiovascular Drugs, 2021, 21 : 535 - 543